AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,468.50GBp
27 May 2015
Change (% chg)

-- (--)
Prev Close
4,468.50p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,638,134
52-wk High
4,931.68p
52-wk Low
4,075.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes... (more)

Overall

Beta: 0.38
Market Cap(Mil.): £55,568.57
Shares Outstanding(Mil.): 1,263.58
Dividend: 125.00
Yield (%): 4.07

Financials

  AZN.L Industry Sector
P/E (TTM): 66.89 37.06 38.97
EPS (TTM): 0.66 -- --
ROI: 3.21 16.25 15.59
ROE: 6.66 17.01 16.59
Search Stocks

AstraZeneca hit after psoriasis drug linked to suicide fears

LONDON - AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.

26 May 2015

AstraZeneca hit after psoriasis drug linked to suicide fears

LONDON, May 26 - AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller.

26 May 2015

Amgen ends partnership with AstraZeneca on psoriasis drug

- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

22 May 2015

UPDATE 2-Amgen ends partnership with AstraZeneca on psoriasis drug

May 22 - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial.

22 May 2015

Amgen ends collaboration with AstraZeneca on inflammation drug

May 22 - Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial.

22 May 2015

UPDATE 1-AstraZeneca to invest $285 mln in Swedish biotech drug factory

LONDON, May 18 - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

18 May 2015

CORRECTED-BRIEF-Astrazeneca to invest $285 mln in biologics facility in Sweden

* To invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

18 May 2015

AstraZeneca to invest $285 mln in Swedish biotech factory

LONDON, May 18 - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

18 May 2015

BRIEF-AstraZeneca to invest in biologics manufacturing facility in Sweden

* Astrazeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

18 May 2015

FDA warns on newer class of type 2 diabetes drugs

- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

15 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$1,000.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks